Gilead Starts Cidofovir Gel Trials In Genital Herpes Patients

28 May 1995

Gilead Sciences has begun a Phase I/II study of cidofovir topical gel in immunocompetent patients with recurrent genital herpes simplex virus (HSV) infection. The patients will receive a single application of either cidofovir (at varying doses) or placebo at four clinical centers in Canada.

Genital herpes is estimated to afflict 30 million people in North America, according to the company. Cidofovir, a member of a new class of antivirals called nucleotide analogs, has shown activity against a wide range of herpes viruses, including HSV-1 and HSV-2, cytomegalovirus, HIV, human papillomavirus and hepatitis B virus.

An additional Phase I/II study of cidofovir topical gel started in the USA and Canada in December 1993, in AIDS patients with HSV infection. This ongoing study is testing a once-daily application for five days on HSV lesions that have not responded to treatment with Glaxo Wellcome's Zovirax (aciclovir), the gold-standard drug for HSV treatment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight